Depomed Inc. (NASDAQ:DEPO) – Research analysts at Roth Capital decreased their Q1 2017 EPS estimates for Depomed in a research note issued on Tuesday. Roth Capital analyst S. Henry now anticipates that the brokerage will post earnings per share of $0.00 for the quarter, down from their previous estimate of $0.03. Roth Capital currently has a “Buy” rating and a $28.00 price objective on the stock. Roth Capital also issued estimates for Depomed’s Q3 2017 earnings at $0.06 EPS and Q4 2017 earnings at $0.15 EPS.

Depomed (NASDAQ:DEPO) last issued its earnings results on Monday, November 7th. The specialty pharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.35 by $0.07. The company had revenue of $111 million for the quarter, compared to the consensus estimate of $127.22 million. Depomed had a negative return on equity of 7.49% and a negative net margin of 16.93%. The firm’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.33 earnings per share.

Earnings History and Estimates for Depomed (NASDAQ:DEPO)

Several other equities research analysts have also issued reports on DEPO. Leerink Swann reiterated a “positive” rating on shares of Depomed in a research report on Monday, July 18th. Janney Montgomery Scott reiterated a “buy” rating and set a $28.00 target price on shares of Depomed in a research report on Monday, July 18th. Cantor Fitzgerald restated a “buy” rating on shares of Depomed in a report on Tuesday, July 19th. Mizuho restated a “positive” rating on shares of Depomed in a report on Thursday, July 21st. Finally, Piper Jaffray Cos. lowered shares of Depomed from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $21.00 to $18.00 in a report on Wednesday, July 27th. One research analyst has rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $23.06.

Depomed (NASDAQ:DEPO) opened at 20.47 on Thursday. The company’s 50-day moving average is $23.67 and its 200 day moving average is $20.79. Depomed has a 52 week low of $12.25 and a 52 week high of $27.02. The company’s market capitalization is $1.26 billion.

A number of institutional investors have recently made changes to their positions in DEPO. KCG Holdings Inc. purchased a new position in shares of Depomed during the third quarter worth about $583,000. Profund Advisors LLC purchased a new position in shares of Depomed during the third quarter worth about $245,000. Principal Financial Group Inc. boosted its position in shares of Depomed by 5.6% in the third quarter. Principal Financial Group Inc. now owns 454,232 shares of the specialty pharmaceutical company’s stock worth $11,352,000 after buying an additional 24,054 shares during the last quarter. Northern Trust Corp boosted its position in shares of Depomed by 0.3% in the third quarter. Northern Trust Corp now owns 740,258 shares of the specialty pharmaceutical company’s stock worth $18,484,000 after buying an additional 1,961 shares during the last quarter. Finally, Suntrust Banks Inc. purchased a new position in shares of Depomed during the third quarter worth about $248,000.

In other Depomed news, VP Thadd M. Vargas sold 11,250 shares of the business’s stock in a transaction on Wednesday, September 21st. The shares were sold at an average price of $25.00, for a total transaction of $281,250.00. Following the transaction, the vice president now directly owns 73,086 shares of the company’s stock, valued at approximately $1,827,150. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 5.12% of the company’s stock.

Depomed Company Profile

5 Day Chart for NASDAQ:DEPO

Receive News & Stock Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related stocks with our FREE daily email newsletter.